Studies aiming at better understanding the causes of low ROC1 expression which might increase cyclin D1 expression in skin melanomas could

highly contribute to the investigation of novel treatments for these tumors. To MedGen Comércio STAT inhibitor e Importação Ltda. for providing anti-ROC1 antibody aliquots for testing, and to Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) for their financial support (grant # 07/53269-6). “
“The authors regret that Agnieszka Kotkiewicz was omitted from the authorship list, which should therefore read as above: Marta Muszalika,*, Ate Dijkstrab, Kornelia Kędziora-Kornatowskaa, Halina Zielińska-Więczkowskac, Tomasz Kornatowskid, Agnieszka Kotkiewicze aDepartment and Clinic of Geriatrics of Nicolaus, Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, ul. Marii

Curie-Skłodowskiej 9, Bydgoszcz 85-094, Poland bGraduate School for Health Research SHARE, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands cDepartment of Pedagogy and Nursing Didactics, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, ul. Techników 3, Bydgoszcz 85-801, Poland dDepartment of Pharmacology and Therapy, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, ul. Marii Curie-Skłodowskiej 9, Bydgoszcz 85-094, Poland eRN-Public Healthcare Team, ul. Kilińskiego 16, 87-800 Włocławek, Poland “
“The authors apologize for reproducing several sections of text from two articles published in the Journal of the National Cancer Institute and The American Journal of Surgery. They also acknowledge LBH589 cost that these articles should have been cited. The authors apologize to the authors and publishers of these articles for their error in reproducing text without any attribution. The details are as follows: (i) Tumor characteristics and clinical outcome of Erlotinib nmr elderly women with breast cancer, Sami G. Diab, Richard M. Elledge, Gary M. Clark, Journal of the National Cancer

Institute, vol. 92, no. 7, April 5 (2000) The following text was reproduced: In the Discussion: This study clearly demonstrates that breast cancer in the elderly has distinctive biologic and clinical characteristics”. And The different approaches to local and systemic treatments in elderly patients with breast cancer have been well documented (refs). This study demonstrates that elderly patients are less likely to receive systemic chemotherapy and radiation therapy. It also demonstrates that older patients undergo less extensive surgical resection than do younger patients. On the other hand, older patients are just as likely to receive systemic endocrine therapy as younger patients. However, because older patients are more likely to have tumors with steroid hormone receptors, one might expect that a greater proportion should receive adjuvant endocrine therapy.